MoHAP reveals new blood test to predict heart diseases

The world’s first and only licensed test (CE Marked) was carried out in cooperation with Abbott Laboratories and it may help clinicians improve the quality of treatment.

MoHAP added that its cooperation with Abbott in this test will make it the world’s first government institution to implement a preventive initiative by which it would be leading the way towards using innovative preventive solutions that can predict cardiovascular diseases.

It will also make the UAE the world’s first country to adopt this new approach including a 10-year heart risk record, which will monitor results and educate doctors continuously.

The global medical trends are focusing now on prevention, as the best way to address the increasing burden of cardiovascular disease. Prevention requires early detection and reduction of hazards, hence the importance of the high-sensitivity cardiac troponin blood test (hsTnI), which can tell if the patient has a risk of cardiovascular diseases.

Dr Youssif Al Serkal, an assistant undersecretary for the Ministry’s Hospitals Sector, stressed the importance of the test especially after being approved by the CE. This technology will support MoHAP’s efforts to improve the outcomes of the National Cardiovascular Diseases Indicator, in accordance with the requirements of the National Agenda 2021.

He said MoHAP aims to enhance its partnerships with global research centres, in coordination with the health authorities in the government and private sectors to achieve the national indicator of reducing cardiovascular disease mortalities, following the significant progress made in the intervention and treatment of heart diseases.

“According to WHO, cardiovascular disease remains the leading cause of death worldwide, thus we are focusing on prevention to reinforce the health system capabilities to assess risks in both youth and elderly,” Al Serkal concluded.